Terumo Corporation and Diabeloop SA Enter into Comprehensive Strategic Partnership Agreement to Expand Their Diabetes Care Offerings
November 17, 2021
Share
Terumo Corporation and the Diabeloop, announced that they have signed an agreement for a comprehensive strategic partnership. With this agreement, in addition to the current joint development of the AID system for Japan, they will work closely to bring Automated Insulin Delivery solutions to Europe with potential further global expansion. The AID system is used for insulin-dependent diabetes management. It automates and personalizes the treatment and contributes to reducing the heavy mental burden associated with the chronic condition. Hosted on a dedicated handset, the Diabeloop-developed self-learning algorithm is connected to a continuous glucose monitor (CGM) and an insulin pump. It analyzes the data in real time, and decides whether to maintain current insulin settings or adjust insulin delivery. In Europe and the US, more and more people with diabetes are using or looking to use AID systems for better glucose control and improved quality of life.
Terumo Corporation specializes in the design, manufacturing and marketing of medical products and equipments. Net sales break down by family of products as follows:
- cardiac surgery devices (53.5%);
- medical products for hospitals (28.6%): medical devices, nutritional additives, oxygen, medical measuring devices (thermometers, tensiometers, glucometers, etc.), etc.;
- sanguine transfusion equipments (17.9%).
Net sales break down geographically as follows: Japan (32.9%), America (29.5%), Europe (19.6%), China (7.4%) and other (10.6%).
TERUMO CORPORATION 
